Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-1167 · 1 trial · 1 indication
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE were reported.
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE were reported.
| Arm | Type | Description |
|---|---|---|
| Panel A: MK-1167 + Donepezil 10mg QD | EXPERIMENTAL | Participants receive 6mg MK-1167 oral loading doses once daily (QD) Days 1 to 7, followed by 3mg MK-1167 oral maintenance doses QD Days 8 to 21. Participants also receive 10mg oral Donepezil on Days -3 to 21. |
| Panel A: Placebo to MK-1167 + Donepezil 10mg QD | PLACEBO_COMPARATOR | Participants receive dose matched placebo to MK-1167 oral QD from Days 1 to 21. Participants also receive 10mg oral Donepezil QD on Days -3 to 21. |
| Panel B: MK-1167 6mg QD + Donepezil 10mg QD | EXPERIMENTAL | Participants receive 6mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10mg oral Donepezil on Days -3 to 31. |
| Panel B: Placebo to MK-1167 + Donepezil 10mg QD | PLACEBO_COMPARATOR | Participants receive dose matched placebo to MK-1167 oral QD from Days 1 to 31. Participants also receive 10mg oral Donepezil QD on Days -3 to 31. |
| Name | Type | Description |
|---|---|---|
| MK-1167 | DRUG | 1 mg and 5 mg oral capsules |
| Donepezil | DRUG | 10 mg oral tablets |
| Placebo | DRUG | MK-1167 matching placebo administered oral capsules |
Inclusion Criteria: * Reports a history of cognitive and functional decline with gradual onset and slow progression for at least 1 year before Screening, that is either corroborated by an informant who knows the subject well or is documented in medical records * Meets the criteria for a diagnosis o...
Top 20 of 30 competitors
MK-1167 is an investigational small molecule being developed by Merck & Company, Inc. (ticker MRK) for Alzheimer's disease dementia. It is in Phase 1 clinical development. The compound has been studied in a single completed trial that enrolled 28 participants in the United States.
MK-1167 is being evaluated for the treatment of Alzheimer's disease dementia. The Phase 1 trial studied it in participants with Alzheimer's disease dementia who were taking stable donepezil treatment. It is investigational and has not been approved for any indication.
MK-1167 is being developed by Merck & Company, Inc., which trades under the ticker MRK. Merck sponsored the Phase 1 trial of MK-1167 in Alzheimer's disease dementia conducted in the United States.
MK-1167 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA for any indication.
MK-1167 has been studied in one completed Phase 1 trial, NCT06285240, titled Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007). The randomized, double-blind, placebo-controlled trial enrolled 28 participants in the United States.